India's biotechnology sector has seen an exponential rise — from 5,365 startups in 2021 to 13,000 in 2025. This growth is driven by policy frameworks such as the BioE3 Policy (Biotechnology for Economy, Environment and Employment) and the National Biopharma Mission. India is now targeting a bioeconomy of $300 billion by 2030, up from $165.7 billion in 2024. The sector encompasses agriculture biotech, industrial biotech, biopharmaceuticals, and bio-energy. India ranks third globally in the Asia-Pacific biotech sector. This has significant implications for Rajasthan, which is developing a biotechnology park in Jaipur and positioning itself as a hub for agri-biotech given its large agricultural sector.
India's Biotech Sector: 5,365 to 13,000 Startups in 4 Years; $300 Billion Bioeconomy Target by 2030
India's biotechnology sector has seen an exponential rise — from 5,365 startups in 2021 to 13,000 in 2025. This growth is driven by policy frameworks such as the BioE3 Policy (Biotechnology for Economy, Environment and Employment) and the National Biopharma Mission. India is now targeting a bioeconomy of $300 billion by 2030, up from $165.7 billion in 2024. The sector encompasses agriculture biotech, industrial biotech, biopharmaceuticals, and bio-energy. India ranks third globally in the Asia-Pacific biotech sector. This has significant implications for Rajasthan, which is developing a biotechnology park in Jaipur and positioning itself as a hub for agri-biotech given its large agricultural sector.
Key facts
- India's biotech startups grew from 500 in 2018 to over 10,000 in 2025.
- India targets a $300 billion bioeconomy by 2030, up from approximately $130 billion in 2024.
- Growth is driven by the BioE3 Policy and National Biopharma Mission.
- India ranks third globally in the Asia-Pacific biotech sector.
- The sector covers agriculture biotech, industrial biotech, biopharmaceuticals and bio-energy.
- Rajasthan is developing a biotechnology park in Jaipur and positioning itself as an agri-biotech hub.
6-axis classification
Appears in these topics
Practice MCQ from this story
SolveTap an option below. Correct or incorrect feedback appears instantly.
India's biotech startup count rose from fewer than 500 in 2014 to what figure by 2025?
Government information released through PIB states that India had fewer than 500 biotechnology startups in 2014 and that the number had increased to over 10,000 by 2025. Therefore, among the options, "Over 10,000" is the correct answer.
Source: DBT India / Finology Blog
Frequently asked questions
How has India's biotech startup ecosystem grown between 2018 and 2025?
India's biotech startups grew exponentially from approximately 500 in 2018 to over 10,000 in 2025. This growth makes India one of the fastest-growing biotech ecosystems globally, driven by policy support and increased R&D investment.
What is India's bioeconomy target for 2030 and what was its value in 2024?
India is targeting a bioeconomy of $300 billion by 2030, up from approximately $130 billion in 2024. This ambitious target is supported by policy frameworks including the BioE3 Policy and the National Biopharma Mission.
What is the BioE3 Policy and what does it stand for?
BioE3 stands for Biotechnology for Economy, Environment and Employment. It is a national policy framework designed to drive India's biotechnology-led economic growth by supporting innovation in agriculture biotech, industrial biotech, biopharmaceuticals, and bio-energy sectors.
What is India's global ranking in the Asia-Pacific biotech sector and how is Rajasthan contributing?
India ranks third globally in the Asia-Pacific biotechnology sector. Rajasthan is developing a biotechnology park in Jaipur and positioning itself as an agri-biotech hub, contributing to the national bioeconomy goals.
Which sectors make up India's biotechnology industry?
India's biotechnology industry encompasses agriculture biotech, industrial biotech, biopharmaceuticals, and bio-energy. The National Biopharma Mission particularly focuses on biopharmaceuticals, which include vaccines, biosimilars, and therapeutic proteins critical for public health.
Was this useful?
Share corrections or missing exam angles with the editorial team.
Send feedback